Issued: 15 August 2024, London
UK
Statement: Zantac (ranitidine) litigation - Florida State
Court Daubert Ruling in Wilson case
·
Florida State Court's
ruling finds in favour of GSK and other defendants, excluding
plaintiff's experts' general and specific causation testimony that
ranitidine was a significant risk factor for Wilson's prostate
cancer
·
Court's ruling is consistent
with scientific consensus that there is no consistent or reliable
evidence that ranitidine increases the risk of any
cancer
·
GSK continues to vigorously
defend itself, including against all claims in other
jurisdictions
GSK plc (LSE/NYSE: GSK) welcomes
today's Daubert ruling by the Florida State Court. In excluding
plaintiffs' expert testimony as unreliable, GSK will now seek
dismissal of the upcoming Wilson case in Florida - whereby
plaintiffs alleged a causal link between ranitidine and prostate
cancer.
Today's decision echoes the December
2022 ruling by Judge Rosenberg in the federal multidistrict
litigation (MDL), which rejected all expert evidence put forward by
the plaintiffs and dismissed all MDL cases alleging bladder,
esophageal, gastric, liver, or pancreatic cancer. Both the MDL and
Florida courts have determined that the methodology used by
plaintiffs' experts is unreliable and fails to meet the Daubert
standard for scientific evidence.
Since 2019, following the 16
epidemiological studies looking at human data regarding the use of
ranitidine, the scientific consensus is that there is no consistent
or reliable evidence that ranitidine increases the risk of any
cancer. Today's ruling reflects the state of that science and
ensures that unreliable and litigation-driven science does not
enter the courtroom.
GSK continues to defend itself
vigorously, including against all remaining claims in other
jurisdictions.
Notes to Editors
* The Daubert standard, established
in the U.S. Supreme Court case Daubert v. Merrell Dow
Pharmaceuticals, Inc. 509 US 579 (1993) provides criteria for
evaluating whether expert testimony is admissible under Federal
Rule of Evidence 702. Under Rule 702 and Daubert, an expert
may offer testimony if he or she is qualified by knowledge,
education, training or experience in a given area and the testimony
offered is reliable, relevant and helpful to the jury. In
applying the Daubert standard, the Court acts as a gatekeeper,
ensuring that expert opinions meet certain standards for
reliability and that speculative or unreliable opinions are not
presented to the jury. In Daubert, the Supreme Court
identified four factors to guide assessment of an expert's
methodology: (1) whether the expert's methodology has been tested
or is capable of being tested; (2) whether the theory or technique
used by the expert has been subjected to peer review and
publication; (3) whether there is a known or potential error rate
of the methodology; and (4) whether the technique has been
generally accepted in the relevant scientific community. The
Daubert standard is applicable to expert testimony in all federal
cases. Many states also have adopted standards identical to
the federal Daubert standard.
The term "Daubert Standard" comes
from the United States Supreme Court case: Daubert v Merrell Dow
Pharmaceuticals Inc 509 US 579 (1993).
About GSK
GSK is a global biopharma company
with a purpose to unite science, technology, and talent to get
ahead of disease together. Find out more at gsk.com.
GSK
enquiries
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
Dan Smith
|
+44 (0) 20 8047 5502
|
(London)
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
Lyndsay Meyer
|
+1 202 302 4595
|
(Washington DC)
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
Camilla Campbell
|
+44 (0) 7803 050238
|
(London)
|
|
Steph Mountifield
|
+44 (0) 7796 707505
|
(London)
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
|
Frannie DeFranco
|
+1 215 751 4855
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK cautions
investors that any forward-looking statements or projections made
by GSK, including those made in this announcement, are subject to
risks and uncertainties that may cause actual results to differ
materially from those projected. Such factors include, but are not
limited to, those described under Item 3.D "Risk factors" in GSK's
Annual Report on Form 20-F for 2023, and GSK's Q2 Results for
2024.
Registered in England & Wales:
No. 3888792
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS